Cdk1 (Cdc2) is a serine/threonine kinase which forms complexes with cyclins A and B which then phosphorylate a variety of target substrates to enable cell cycle progression. Therefore, Cdk1 is a marker for proliferating tumour cells.
| Inventor | Institute |
|---|---|
| Julian Gannon | Cancer Research UK, London Research Institute: Clare Hall Laboratories |
| Cat. #: | 151037 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell biology;Neurobiology |
| Application: | ELISA ; IHC ; IP ; WB |
| Target: | Cyclin dependent kinase 1 (Cdk1, cdc2) |
| Reactivity: | Chicken ; Human ; Mouse ; Rat ; Xenopus laevis |
| Clone: | 17 (A17) |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | Cyclin-Dependent Kinase 1; Cell Division Cycle 2, G1 To S And G2 To M; Cell Division Control Protein 2 Homolog; Cell Division Protein Kinase 1; P34 Protein Kinase; P34CDC2; CDC28A; CDC2; Cell Cycle Controller CDC2; CDKN1 |
|---|---|
| Product description: | Cdk1 (Cdc2) is a serine/threonine kinase which forms complexes with cyclins A and B which then phosphorylate a variety of target substrates to enable cell cycle progression. Therefore, Cdk1 is a marker for proliferating tumour cells. |
| Conjugation: | Unconjugated |
| Isotype: | IgG2a |
| Molecular weight: | 34 kDa |
| Immunogen: | A carboxy-terminal fragment starting at methionine 85 of p34 cdc2 (Xenopus laevis). |
| Myeloma used: | Sp2/0-Ag14 |
| Target background: | Cdk1 (Cdc2) is a serine/threonine kinase which forms complexes with cyclins A and B which then phosphorylate a variety of target substrates to enable cell cycle progression. Therefore, Cdk1 is a marker for proliferating tumour cells. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Zhou et al. 2015. Platelets. :1-11. PMID: 26325015. Platelets promote cartilage repair and chondrocyte proliferation via ADP in a rodent model of osteoarthritis. Coulonval et al. 2011. Mol Biol Cell. 22(21):3971-85. PMID: 21900495. Coupling of T161 and T14 phosphorylations protects cyclin B-CDK1 from premature activation. Gannon et al. 1998. Genes Cells. 3(1):17-27. PMID: 9581979. A measure of the mitotic index: studies of the abundance and half-life of p34cdc2 in cultured cells and normal and neoplastic tissues. Goodger et al. 1996. J Pathol. 178(4):422-8. PMID: 8691321. The localization of p34cdc2 in the cells of normal, hyperplastic, and malignant epithelial and lymphoid tissues of the oral cavity. Doussis-Anagnostopoulou et al. 1994. Histopathology. 24(4):335-40. PMID: 8045523. Distribution of the cdc2 gene product in normal tissues: an immunocytochemical study using four new monoclonal antibodies. Kobayashi et al. 1992. Mol Biol Cell. 3(11):1279-94. PMID: 1333843. Identification of the domains in cyclin A required for binding to, and activation of, p34cdc2 and p32cdk2 protein kinase subunits. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151016 | Anti-CyclinA [E72.1] |
Key Info
Anti-CyclinA [E72.1]
|
View Tool | |||||||||||||||||||
| 151023 | Anti-IL12 [1-1D5] |
Key Info
Anti-IL12 [1-1D5]
|
View Tool | |||||||||||||||||||
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
| 151038 | Anti-Cytochrome P450 4A2, 4A3 [Clo4] |
Key Info
Anti-Cytochrome P450 4A2, 4A3 [Clo4]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.